Review of the safety and feasibility of rapid infusion of rituximab. - Wikidata - awgldk - TriplyDB

Review of the safety and feasibility of rapid infusion of rituximab.

Review of the safety and feasibility of rapid infusion of rituximab.

http://www.wikidata.org/entity/Q37769107

about

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews.Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.Rituximab therapy in nephrotic syndrome: implications for patients' management.Rapid infusion rituximab for maintenance therapy: is it feasible?A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population.Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders.

P2860

Q33672391-30D32A36-E8F0-498C-936D-9026FA9C46DA Q34763541-41D46C5F-12CC-4E79-A174-3F4E0B217A38 Q37910273-047D5059-F9D9-46D7-BD97-66B838C3B1D3 Q38075787-0196BDA5-2DC9-4767-8258-D168C04C02AD Q41826129-2B0255D7-391C-42DC-9384-8A05EFA13CC4 Q42376931-C0E388D2-6480-49A9-A8FF-C41C77D2D22A Q44654704-4E5ADF7E-1C37-40FE-8D30-0EB2C06A2922 Q47973396-4B25D744-1CCF-48C8-A657-80C28262071E

P2860

Review of the safety and feasibility of rapid infusion of rituximab.

http://www.wikidata.org/entity/Q37769107

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Review of the safety and feasibility of rapid infusion of rituximab.

@en

Review of the safety and feasibility of rapid infusion of rituximab.

@nl

type

label

Review of the safety and feasibility of rapid infusion of rituximab.

@en

Review of the safety and feasibility of rapid infusion of rituximab.

@nl

prefLabel

Review of the safety and feasibility of rapid infusion of rituximab.

@en

Review of the safety and feasibility of rapid infusion of rituximab.

@nl

P1433

Q37769107-EC19E54C-3E19-4FCE-A097-6BFD8C38AFAD

P1476

Q37769107-FE5FA855-F462-46D7-B24A-43A2D658AEC1

P2093

Q37769107-6129DA1E-C121-4C99-BDB0-CC13B1B5C6C7

P2860

Q37769107-0BD35F88-60D8-41C7-8E5B-EEC90FCAB39B

Q37769107-12F9B85F-3A11-443C-B190-B902F95A40C6

Q37769107-346382F7-5DDB-430E-B443-DA2DC3546D29

Q37769107-36D80A87-927B-4D6A-ACFE-829172959A68

Q37769107-5E2EF299-8A65-4B8A-9AF0-AC30026A81D9

Q37769107-919C90FE-1C44-4A45-9FDC-76A7742EA61A

Q37769107-9ABC7A3E-0FE6-4033-8A5C-99DACD5D2AC0

Q37769107-DF858B40-D67D-48B0-BB3F-97E3085DEA94

Q37769107-F071C9A8-F287-421B-AFF1-FF01C19250E4

P304

Q37769107-69518383-FC78-4495-95F0-6810F12CFEA9

P31

Q37769107-3D73402E-BDE7-4940-912C-6FF687C2B352

P356

Q37769107-70E4AA70-18DC-4826-9160-8F953AE5F90A

P407

Q37769107-B6BC46EA-C1D7-4580-8BFD-419B8B7ABF36

P433

Q37769107-A41DE9D4-F665-422E-8309-89E2D6326AB6

P478

Q37769107-EC196F57-5618-478A-B5A2-14F239589AE4

P577

Q37769107-6F049547-87E1-4D93-AE41-BDCE57D6E301

P698

Q37769107-BE26D65A-71D1-45BD-A8CF-D59E892DE1C9

P932

Q37769107-F5DD5259-4853-4806-8A02-76D2F37B35D3

P356

P1433

Journal of Oncology Practice

P1476

Review of the safety and feasibility of rapid infusion of rituximab.

@en

P2093

Jill Atmar

http://www.w3.org/2001/XMLSchema#string

P2860

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Rapid infusion of rituximab over 60 min.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.

P304

91-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.200001

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20592783

http://www.w3.org/2001/XMLSchema#string

P932

2835489

http://www.w3.org/2001/XMLSchema#string